^
Association details:
| Biomarker: | BCR-ABL1 fusion |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Scemblix (asciminib) (Bcr-abl inhibitor, STAMP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
FRONTLINE ASCIMINIB COMBINATION IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS. THE FASCINATION TRIAL.
Published date:
05/11/2023
Excerpt:
The aim of the study was to pilot asciminib in combination with ATP competing tyrosine kinase inhibitors (TKI) asfirst-line therapies in CML pts to improve the rate of deep molecular response...Adult pts with newly diagnosed BCR::ABL1-positive CML were included in the study...The combination of asciminib as frontline therapy with ATP competing BCR::ABL1 inhibitors is associated with a high rate of deep molecular response...